Cariprazine (Chengdu Kanghong) vs Cariprazine (Vraylar)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D3/D2 receptor (partial agonist) · full Schizophrenia pipeline
Cariprazine (Chengdu Kanghong)
Developed by Chengdu Kanghong Pharmaceutical
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Cariprazine (Vraylar)
Marketed by AbbVie and partners
NCT01104766 · Phase 3 · completed
The trial randomized 617 participants to cariprazine 3 mg, cariprazine 6 mg, aripiprazole 10 mg, or placebo, with participants, investigators, and outcome assessors masked. The prespecified clinical primary endpoint, change in PANSS total score at week 6, was significantly improved with both cariprazine doses versus placebo (p=0.0044 and p<0.0001), supporting a strong evidence grade.
Next expected readout: December 2026 · NCT03817502 (registry estimate)
Reported efficacy
Measurement of Schizophrenia Symptoms: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score. (Baseline to Week 6): Measurement of Schizophrenia Symptoms: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score. (Baseline to Week 6): Cariprazine 3.0 mg -20.2 Units on a Scale (Standard Error 1.5) | Cariprazine 6.0mg -23 Units on a Scale (Standard Error 1.5) vs Placebo -14.3 Units on a Scale (Standard Error 1.5) | Aripiprazole 10.0 mg -21.2 Units on a Scale (Standard Error 1.4) (met)
Result source: NCT01104766
Results for Schizophrenia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Cariprazine (Chengdu Kanghong) | Cariprazine (Vraylar) |
|---|---|---|
| PANSS total, change | —Trial running · NCT06589817 | -23 vs -14.3−8.7 vs placeboNCT011047669 other results
|
| CGI-S, change | —Trial running · NCT06589817 | -1.5 vs -1−0.5 vs placeboNCT011047669 other results
|
| PANSS response | —Trial running · NCT06589817 | —Not posted · NCT04578756 |
| PSP, change | —Trial running · NCT06589817 | —Not posted · NCT04578756 |
| Relapse (% of patients) | —Trial running · NCT06589817 | —Not posted · NCT04578756 |
PANSS total, change
- Cariprazine (Chengdu Kanghong)
- —Trial running · NCT06589817
- Cariprazine (Vraylar)
- -23 vs -14.3−8.7 vs placeboNCT01104766
9 other results
- -14 vs -9.5 NCT01625000
- -13.8 vs -9.5 NCT01625000
- -20.2 vs -14.3 NCT01104766
- -10.4 vs -9.5 NCT01625000
- -22.8 vs -16 NCT01104779
- -25.9 vs -16 NCT01104779
- -17.3 vs -9.5 NCT00694707
- -20.2 vs -9.5 NCT00694707
- -18.7 vs -9.5 NCT00694707
CGI-S, change
- Cariprazine (Chengdu Kanghong)
- —Trial running · NCT06589817
- Cariprazine (Vraylar)
- -1.5 vs -1−0.5 vs placeboNCT01104766
9 other results
- -0.7 vs -0.6 NCT01625000
- -0.8 vs -0.6 NCT01625000
- -1.4 vs -1 NCT01104766
- -0.7 vs -0.6 NCT01625000
- -1.4 vs -1 NCT01104779
- -1.6 vs -1 NCT01104779
- -0.9 vs -0.6 NCT00694707
- -1.2 vs -0.6 NCT00694707
- -1.1 vs -0.6 NCT00694707
PANSS response
- Cariprazine (Chengdu Kanghong)
- —Trial running · NCT06589817
- Cariprazine (Vraylar)
- —Not posted · NCT04578756
PSP, change
- Cariprazine (Chengdu Kanghong)
- —Trial running · NCT06589817
- Cariprazine (Vraylar)
- —Not posted · NCT04578756
Relapse (% of patients)
- Cariprazine (Chengdu Kanghong)
- —Trial running · NCT06589817
- Cariprazine (Vraylar)
- —Not posted · NCT04578756
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Cariprazine (Chengdu Kanghong): no structured comparison results are available for Schizophrenia.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Cariprazine (Chengdu Kanghong): 0 of 4 rows · Cariprazine (Vraylar): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Cariprazine (Vraylar) |
|---|---|
| Dropout rate | 38.2%6.0mga NCT01104766 · Phase 3 · monotherapy · Schizophrenia · phase 3 show 23 more results32.9%3.0 mg NCT01104766 · Phase 3 · monotherapy · Schizophrenia · phase 3 36.4%3-6 mg/Day NCT01104779 · Phase 3 · monotherapy · Schizophrenia · phase 3 41.9%6-9 mg/Day NCT01104779 · Phase 3 · monotherapy · Schizophrenia · phase 3 — NCT01412060 · Phase 3 · registry result, not featured evidence 69.9% NCT01104792 · Phase 3 · registry result, not featured evidence 41.4%9mg NCT01626872 · Phase 2/3 · registry result, not featured evidence 60.6%6mg NCT01626872 · Phase 2/3 · registry result, not featured evidence 64.2%3mg NCT01626872 · Phase 2/3 · registry result, not featured evidence 49.3%9mg NCT01625000 · Phase 2/3 · registry result, not featured evidence 39.1%6mg NCT01625000 · Phase 2/3 · registry result, not featured evidence 41.3%3mg NCT01625000 · Phase 2/3 · registry result, not featured evidence 62.7%1.5-9mg NCT01625897 · Phase 2/3 · registry result, not featured evidence 28.6%1.5-9 mg NCT01626885 · Phase 2/3 · registry result, not featured evidence 36.4%9 mg NCT01626859 · Phase 2/3 · registry result, not featured evidence 50%6 mg NCT01626859 · Phase 2/3 · registry result, not featured evidence 18.2%3 mg NCT01626859 · Phase 2/3 · registry result, not featured evidence 50.5% NCT00839852 · Phase 2 · registry result, not featured evidence 10%6 mg NCT00862992 · Phase 2 · registry result, not featured evidence 25%3 mg NCT00862992 · Phase 2 · registry result, not featured evidence 25%12.5 mg NCT00862992 · Phase 2 · registry result, not featured evidence 37.9%1.5 mg NCT00694707 · Phase 2 · registry result, not featured evidence 33.8%4.5 mg NCT00694707 · Phase 2 · registry result, not featured evidence 34.7%3.0 mg NCT00694707 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 12.7%6.0mga NCT01104766 · Phase 3 · monotherapy · Schizophrenia · phase 3 show 23 more results9.7%3.0 mg NCT01104766 · Phase 3 · monotherapy · Schizophrenia · phase 3 9.3%3-6 mg/Day NCT01104779 · Phase 3 · monotherapy · Schizophrenia · phase 3 8.8%6-9 mg/Day NCT01104779 · Phase 3 · monotherapy · Schizophrenia · phase 3 — NCT01412060 · Phase 3 · registry result, not featured evidence 10.2% NCT01104792 · Phase 3 · registry result, not featured evidence 13.8%9mg NCT01626872 · Phase 2/3 · registry result, not featured evidence 25.7%6mg NCT01626872 · Phase 2/3 · registry result, not featured evidence 24.7%3mg NCT01626872 · Phase 2/3 · registry result, not featured evidence 16.4%9mg NCT01625000 · Phase 2/3 · registry result, not featured evidence 14.3%6mg NCT01625000 · Phase 2/3 · registry result, not featured evidence 11.9%3mg NCT01625000 · Phase 2/3 · registry result, not featured evidence 32.5%1.5-9mg NCT01625897 · Phase 2/3 · registry result, not featured evidence 19%1.5-9 mg NCT01626885 · Phase 2/3 · registry result, not featured evidence 18.2%9 mg NCT01626859 · Phase 2/3 · registry result, not featured evidence 18.8%6 mg NCT01626859 · Phase 2/3 · registry result, not featured evidence 9.1%3 mg NCT01626859 · Phase 2/3 · registry result, not featured evidence 10.8% NCT00839852 · Phase 2 · registry result, not featured evidence 10%6 mg NCT00862992 · Phase 2 · registry result, not featured evidence 16.7%3 mg NCT00862992 · Phase 2 · registry result, not featured evidence 8.3%12.5 mg NCT00862992 · Phase 2 · registry result, not featured evidence 9.7%1.5 mg NCT00694707 · Phase 2 · registry result, not featured evidence 8.1%4.5 mg NCT00694707 · Phase 2 · registry result, not featured evidence 5.4%3.0 mg NCT00694707 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 4.5%6.0mga NCT01104766 · Phase 3 · monotherapy · Schizophrenia · phase 3 show 23 more results2.6%3.0 mg NCT01104766 · Phase 3 · monotherapy · Schizophrenia · phase 3 5.4%3-6 mg/Day NCT01104779 · Phase 3 · monotherapy · Schizophrenia · phase 3 2.4%6-9 mg/Day NCT01104779 · Phase 3 · monotherapy · Schizophrenia · phase 3 13.9% NCT01412060 · Phase 3 · registry result, not featured evidence 10.1% NCT01104792 · Phase 3 · registry result, not featured evidence 24.1%9mg NCT01626872 · Phase 2/3 · registry result, not featured evidence 30.3%6mg NCT01626872 · Phase 2/3 · registry result, not featured evidence 17.3%3mg NCT01626872 · Phase 2/3 · registry result, not featured evidence 6%9mg NCT01625000 · Phase 2/3 · registry result, not featured evidence 12%6mg NCT01625000 · Phase 2/3 · registry result, not featured evidence 9.5%3mg NCT01625000 · Phase 2/3 · registry result, not featured evidence 15.7%1.5-9mg NCT01625897 · Phase 2/3 · registry result, not featured evidence 4.8%1.5-9 mg NCT01626885 · Phase 2/3 · registry result, not featured evidence 0%9 mg NCT01626859 · Phase 2/3 · registry result, not featured evidence 12.5%6 mg NCT01626859 · Phase 2/3 · registry result, not featured evidence 0%3 mg NCT01626859 · Phase 2/3 · registry result, not featured evidence 12.9% NCT00839852 · Phase 2 · registry result, not featured evidence 10%6 mg NCT00862992 · Phase 2 · registry result, not featured evidence 25%3 mg NCT00862992 · Phase 2 · registry result, not featured evidence 16.7%12.5 mg NCT00862992 · Phase 2 · registry result, not featured evidence 3.4%1.5 mg NCT00694707 · Phase 2 · registry result, not featured evidence 2.7%4.5 mg NCT00694707 · Phase 2 · registry result, not featured evidence 0%3.0 mg NCT00694707 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 6.0mga akathisia 15.3% (placebo 5.9%) insomnia 14% (placebo 16.3%) headache 10.2% (placebo 11.1%) NCT01104766 · Phase 3 · monotherapy · Schizophrenia · phase 3 show 23 more results3.0 mg insomnia 13.5% (placebo 16.3%) akathisia 7.7% (placebo 5.9%) anxiety 7.7% (placebo 7.2%) NCT01104766 · Phase 3 · monotherapy · Schizophrenia · phase 3 3-6 mg/Day akathisia 15.9% (placebo 3.4%) constipation 9.3% (placebo 3.4%) headache 9.3% (placebo 12.9%) NCT01104779 · Phase 3 · monotherapy · Schizophrenia · phase 3 6-9 mg/Day akathisia 16.9% (placebo 3.4%) headache 16.2% (placebo 12.9%) insomnia 10.8% (placebo 10.9%) NCT01104779 · Phase 3 · monotherapy · Schizophrenia · phase 3 headache 7.9% (placebo 7.1%) insomnia 7.9% (placebo 8.1%) nasopharyngitis 7.9% (placebo 5.1%) NCT01412060 · Phase 3 · registry result, not featured evidence akathisia 20.1% headache 17.7% insomnia 17.7% NCT01104792 · Phase 3 · registry result, not featured evidence 9mg nasopharyngitis 22.4% schizophrenia 19% insomnia 13.8% NCT01626872 · Phase 2/3 · registry result, not featured evidence 6mg akathisia 13.8% nasopharyngitis 11.9% insomnia 11% NCT01626872 · Phase 2/3 · registry result, not featured evidence 3mg nasopharyngitis 25.9% akathisia 18.5% schizophrenia 14.8% NCT01626872 · Phase 2/3 · registry result, not featured evidence 9mg schizophrenia 19.4% (placebo 18.3%) constipation 17.9% (placebo 11.9%) extrapyramidal disorder 16.4% (placebo 9.5%) NCT01625000 · Phase 2/3 · registry result, not featured evidence 6mg constipation 15% (placebo 11.9%) akathisia 14.3% (placebo 7.9%) extrapyramidal disorder 14.3% (placebo 9.5%) NCT01625000 · Phase 2/3 · registry result, not featured evidence 3mg akathisia 22.2% (placebo 7.9%) constipation 16.7% (placebo 11.9%) headache 15.1% (placebo 11.1%) NCT01625000 · Phase 2/3 · registry result, not featured evidence 1.5-9mg schizophrenia 33.7% nasopharyngitis 31.3% nausea 18.1% NCT01625897 · Phase 2/3 · registry result, not featured evidence 1.5-9 mg nasopharyngitis 42.9% schizophrenia 19% headache 16.7% NCT01626885 · Phase 2/3 · registry result, not featured evidence 9 mg akathisia 27.3% insomnia 27.3% restlessness 18.2% NCT01626859 · Phase 2/3 · registry result, not featured evidence 6 mg nasopharyngitis 37.5% schizophrenia 31.3% insomnia 25% NCT01626859 · Phase 2/3 · registry result, not featured evidence 3 mg restlessness 54.5% akathisia 45.5% nasopharyngitis 27.3% NCT01626859 · Phase 2/3 · registry result, not featured evidence akathisia 14% insomnia 14% weight increased 11.8% NCT00839852 · Phase 2 · registry result, not featured evidence 6 mg insomnia 30% nasopharyngitis 30% toothache 20% NCT00862992 · Phase 2 · registry result, not featured evidence 3 mg insomnia 33.3% diarrhoea 16.7% nasopharyngitis 16.7% NCT00862992 · Phase 2 · registry result, not featured evidence 12.5 mg akathisia 25% alanine aminotransferase increased 25% blood creatine phosphokinase increased 25% NCT00862992 · Phase 2 · registry result, not featured evidence 1.5 mg extrapyramidal disorder 11.7% (placebo 6%) headache 11.7% (placebo 11.3%) insomnia 10.3% (placebo 7.3%) NCT00694707 · Phase 2 · registry result, not featured evidence 4.5 mg insomnia 16.3% (placebo 7.3%) extrapyramidal disorder 12.9% (placebo 6%) akathisia 8.8% (placebo 5.3%) NCT00694707 · Phase 2 · registry result, not featured evidence 3.0 mg insomnia 16.4% (placebo 7.3%) akathisia 9.6% (placebo 5.3%) extrapyramidal disorder 9.6% (placebo 6%) NCT00694707 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 20 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Cariprazine (Vraylar)
show 9 more results
show 9 more results
show 3 more results
show 3 more results
show 2 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Cariprazine (Chengdu Kanghong)'s landscape · Cariprazine (Vraylar)'s landscape